Home Cart Sign in  
Chemical Structure| 1009298-09-2 Chemical Structure| 1009298-09-2

Structure of AZD-8055
CAS No.: 1009298-09-2

Chemical Structure| 1009298-09-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM, inhibiting both mTORC1 and mTORC2.

Synonyms: CCG-168

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD-8055

CAS No. :1009298-09-2
Formula : C25H31N5O4
M.W : 465.54
SMILES Code : OCC1=CC(C2=NC3=NC(N4[C@@H](C)COCC4)=NC(N5[C@@H](C)COCC5)=C3C=C2)=CC=C1OC
Synonyms :
CCG-168
MDL No. :MFCD16660191
InChI Key :KVLFRAWTRWDEDF-IRXDYDNUSA-N
Pubchem ID :25262965

Safety of AZD-8055

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AZD-8055

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • mTOR

    mTOR (truncated), IC50:0.13 nM

    mTOR (full length), IC50:0.8 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00999882 Cancer Advanc... More >>ed Hepatocellular Carcinoma Less << Phase 1 Completed - Hong Kong ... More >> Research Site Hong Kong, Hong Kong Korea, Republic of Research Site Seongnam, Gyeonggi-do, Korea, Republic of Research Site Seoul, Korea, Republic of Less <<
NCT01194193 Cancer Advanc... More >>ed Solid Tumours Lymphomas Less << Phase 1 Withdrawn(Amendment to study c... More >>ompound development programme) Less << - -
NCT00973076 Cancer Solid ... More >>Tumors Advanced Solid Malignancies Less << Phase 1 Completed - Japan ... More >> Research Site Tokyo, Japan Less <<
NCT01316809 Glioblastoma Multiforme ... More >> Anaplastic Astrocytoma Anaplastic Oligodendroglioma Malignant Glioma Brainstem Glioma Less << Phase 1 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00731263 Solid Tumors Phase 1 Completed - United States, New York ... More >> Research Site New York, New York, United States, 10065 United States, Texas Research Site Houston, Texas, United States France Research Site Clichy, France United Kingdom Research Site Sutton, Surrey, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.21mL

10.74mL

2.15mL

1.07mL

21.48mL

4.30mL

2.15mL

References

 

Historical Records

Categories